Global EditionASIA 中文双语Français
China
Home / China / Latest

Researcher plays down talk of anti-virus drug success

The US drug remdesivir had achieved a remarkable effect on 761 patients participating in the first day of the drug's clinical trial.

By WANG XIAODONG | chinadaily.com.cn | Updated: 2020-02-06 22:33
Share
Share - WeChat
FILE PHOTO: A Gilead Sciences Inc logo is seen outside the company headquarters in Foster City, California, US May 1, 2018. [Photo/Agencies]

Too early to draw conclusions, says hospital chief

A drug undergoing clinical research at a hospital in Wuhan, Hubei province, has not yet proven to be effective in treating the novel coronavirus, despite rumors to the contrary, a scientist in charge of the research has said.

Remdesivir, a drug being developed by United States-based pharmaceutical company Gilead, was being tested to see whether it could be used to treat patients with pneumonia caused by the virus in Wuhan Jinyintan Hospital, in Wuhan, the outbreak epicenter, on Wednesday.

On Thursday evening rumors began spreading online saying the first day of trial had achieved a remarkable effect on 761 patients participating in the research.

But Cao Bin, vice-president of the China-Japan Friendship Hospital, dismissed this, saying research has only just started and no results have been achieved yet, according to a report by China Youth Daily.

In a statement at the end of last month, Gilead said Remdesivir had not gained approval to enter the market in any country, and its safety and effectiveness had not been proven.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US